Synthesis and biological evaluation of new salicylate macrolactones from anacardic acids by Logrado, Lucio Paulo Lima et al.
J. Braz. Chem. Soc., Vol. 16, No. 6A, 1217-1225, 2005.
Printed in Brazil - ©2005  Sociedade Brasileira de Química




Synthesis and Biological Evaluation of New Salicylate Macrolactones from Anacardic Acids
Lúcio P. L. Logradoa, Dâmaris Silveirab, Luiz A. S. Romeiroc, Manoel O. de Moraesd, Bruno C.
Cavalcanti d, Letícia V. Costa-Lotufo d, Cláudia do Ó Pessoa d and Maria Lucilia dos Santos*,a
aLaboratório de Isolamento e Transformação de Moléculas Orgânicas, Instituto de Química and bFaculdade de
Ciências da Saúde, Universidade de Brasília, Campus Darcy Ribeiro, 70904-970 Brasília – DF, Brazil
cNúcleo de Química Bioorgânica e Medicinal, Universidade Católica de Brasília, 71966-700 Taguatinga – DF, Brazil
dLaboratório de Oncologia Experimental, Universidade Federal do Ceará, 60431-970 Fortaleza – CE, Brazil
No âmbito de uma linha de pesquisa que visa a obtenção de novas substâncias bioativas, a partir
de lipídeos fenólicos não-isoprenóides de Anacardium occidentale, descrevemos a síntese e avaliação
citotóxica de novas macrolactonas salicílicas, preparadas a partir da mistura de ácidos anacárdicos,
principal constituinte do líquido da casca da castanha de caju (LCC) in natura.
In connection with our ongoing investigation in the search for new bioactive compounds using
non-isoprenoid phenolic lipids from Anacardium occidentale as starting material, we describe the
synthesis and cytotoxicity screening of some novel salicylate macrolactones prepared from anacardic
acids, the major constitutents of natural cashew nut-shell liquid (CNSL).
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Introduction
Non-isoprenoid phenolic lipids exist in plants from a
number of different families, notably the Anacardiaceae
shrub, many small plants, and certain bacterial sources.
The cashew tree (Anacardium occidentale), a species
originally native to Brazil where it is still cultivated, also
grown in a large number of other tropical and sub-tropical
countries, represents one of the major and cheapest sources
of this class of compounds.1
As the main component of natural cashew nut-shell
liquid (CNSL), anacardic acids (1) are the most widely
distributed phenolic lipids. Chemically, the anacardic acids
feature a convenient salicylic acid system and a long side-
chain at the 6-position, in which a double bond is found at
C-8 in the monoene, diene and triene components (Figure
1). Anacardic acids are reported to exhibit a variety of
biological activities,2 and also have stimulated much
research in order to prepare drug analogues for application
in several fields.3
In the course of ongoing investigations aiming at new
drug candidates, the particular structural behavior and
abundance of anacardic acids have prompted us to search for
a strategy to convert these materials into analogues of an
emerging family of antitumor natural products, for example:
oximidines I, II, and III,4 apicularens A and B,5 and
salicylhalamides A and B6 (Figure 2), which present a benzo-
fused macrolactone bearing an unusual N-acylated enamide
Figure 1. Anacardic acids.
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side-chain. Related to the fact that these benzolactone
enamides do not display any significant structural correlations
to the profiles of known anti-cancer drugs, they constitute a
very attractive new class of lead compounds in the search for
antineoplastic agents and have therefore shown considerable
interest concerning to isolation, chemical synthesis and
mechanistic studies of the biochemical mode of action.4-7
Other macrolactones structurally related to the above
macrolides include lasiodiplodin,8 cis- and trans-
resorcylide,9 and curvularin10 (Figure 3). These orsellinic
acid type macrolides also have attracted the attention of
many synthetic chemists regarding both chemical and
physiological activities.11-13 For instance, methyl-
dehydrolasiodiplodin, a mixture of geometrical isomers
used as a precursor for the synthesis of lasiodiplodin,
exhibits a rather uniform in vitro activity against human
tumors e.g. leukemia, lung, colon, melanoma, ovarian,
renal, prostate and breast.14
A few years ago, we reported the synthesis of
lasiodiplodin from the non-isoprenoid phenolic lipids of
cashew nut-shell liquid15 as well as the salicylate
macrolactone 2 (Figure 4).16 Supported by the structural
relationship of the compound 2 with the naturally
occurring macrolides shown in Figures 2 and 3, a
cytotoxicity study on this simplified analogue was
initiated.
Compound 2 showed pronounced cytotoxicity in the
brine shrimp lethality assay (Artemia salina).17 Since this
protocol has been used to access antitumor potential in
preliminary test, this result has encouraged us to prepare
structural variants of macrolactone 2 in order to establish the
first structure-activity relationships based on cytotoxic assays.
Herein we provide a full account of the experimental
details of earlier communications16 and add new results. In
particular, we report the synthetic protocols for the
preparation of the salicylate macrolactone 2 and its
Figure 3. Orsellinic acid type macrolides.
Figure 2. Benzolactone enamides.
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chemical transformations into related macrolides modified
at either the C-13 or the C-14 positions (Figure 4, Scheme
1). Furthermore, we describe the results of the cytotoxicity
screening performed on these analogues.
Results and Discussion
Chemistry
As shown in Scheme 1, our approach for the synthesis
of the title compounds is an extension of a previous work
involving the use of inexpensive and readily available
anacardic acids (1).
The heterogeneous mixture of anacardic acids (1) was
separated from fresh natural CNSL essentially by the same
procedures described in the literature18 and was
quantitatively converted into 3, on a multigram scale, by
treatment with dimethyl sulphate under phase transfer
catalysis.19 The mixture of dialkylated anacardic acids
was submitted to ozonolysis, followed by reductive
cleavage of the derived ozonides with sodium
borohydride, furnishing the alcohol 4 in 85% yield.
Hydrolysis of the ester group in 4 required rather severe
conditions and was accomplished by using aqueous
potassium hydroxide (10 mol L-1) in ethylene glycol at
165 oC.
The resulting hydroxyacid 5 was converted into
macrolide 2 under high dilution conditions and nitrogen
atmosphere in 66% yield, employing Mukaiyama’s
procedure.20 The conversion of the macrolactone 2 into
the analogues 9 and 10 commenced with benzylic
bromination, according to classical conditions (NBS-
benzoyl peroxide). After several attempts, we found that
the bromine lactone 6 was quantitatively converted into
trans-unsaturated lactone 7 by treatment with DBU in
refluxing benzene under a nitrogen atmosphere.
Two distinct methods were explored toward the
epoxidation of the double bond, either by treatment
with performic acid or m-CPBA. Gratifyingly, in the
latter case 7 was smoothly epoxidized to furnish 8 in
98% yield. The epoxide opening was investigated under
various conditions by using heterogeneous catalytic
hydrogenation in a Parr apparatus. The best result, i.e.
97%, was obtained with 5% Pd-C in ethanol, under 4
atm of hydrogen pressure. The oxidation of the hydroxyl
group in 9 was achieved by the classical Jones protocol
in ether at room temperature. By means of this
methodology, compound 9 was successfully converted
into the keto macrolactone 10, in 96% yield.
The spectral properties of the all acyclic precursors
and the macrocyclic lactone 2 are in accordance to the
data previously reported.16 The 1H and 13C-NMR
chemical shifts of the macrocyclic lactone 2 and new
analogues 6 to 10 were confirmed by COSY (Correlated
Spectroscopy), HMQC (Heteronuclear Multiple-
Scheme 1. Reagents and conditions: (a) Me2SO4, CH2Cl2, NaOH, Aliquat®, rt; (b) i. O3, CH2Cl2, MeOH, -70 oC; ii. NaBH4; (c) KOH, HOCH2CH2OH,
165 oC; (d) 2-chloro-1-methylpyridinium iodide, CH2Cl2, CH3CN, Et3N, reflux, under nitrogen atmosphere; (e) NBS, benzoyl peroxide, PhH,
reflux, under nitrogen atmosphere; (f) DBU, PhH, reflux; (g) m-CPBA, CH2Cl2, rt; (h) H2, Pd/C, 4 atm, rt; (i) Jones, ether, rt.
Figure 4. Simplified analogue of salicylate macrolactones.
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Quantum Correlation), HMBC (Heteronuclear Multiple-
Bond Correlation), and NOESY (Nuclear Overhauser
Effect Spectroscopy). The multiplicities of the carbon
signals of all compounds were determined by DEPT
(Distortion-less Enhancement by Polarization Transfer)
experiments. The presence of bromine in 6 was also
confirmed by the quite intense M + 1 and M + 2 peaks
(m/z 341 and 343, 1:1) as determined by high-pressure
liquid chromatography electrospray mass spectroscopy
(HPLC-ESI-MS) experiments. The assignments of the
1H and 13C NMR peaks for the acyclic precursors and
macrocyclic lactones were described according to Figure
5. These spectra data will be further explored in
connection with a study underway utilizing a NMR
computer-aided approach and X-ray crystallography in
order to establish the conformational structure of all
new macrolactones.
Cytotoxicity screening
Lethality against brine shrimp has been successfully used
in order to detect antitumor and pesticidal compounds.
 
The
Artemia salina assays of the novel synthesized macrolides
2 and 6-10 were performed essentially according to Meyer’s
method.17 
 
This methodology has been described as a simple,
inexpensive, and convenient bioassay system, which has
mostly been employed for screening of general bioactivity
or as a general measure of toxicity, as well as in structure-
activity relationship studies. Furthermore, it is positively
correlated to 9KB cell toxicity.21 Matthews suggests the use
of this protocol for the discovery of compounds with ability
to protect against damage by active oxygen species (AOS).22
Compounds 2 and 10 have been found to display
significant toxicity against Artemia salina. As a matter of
fact, 2 (DL50 32.12 ppm, 0.032 mg mL-1) is nearly 3-times
more potent than 10 (DL50 98.42 ppm, 0.098 mg mL-1). The
latter compound is less active than the active controls e.g.
lapachol (DL50 76.82 ppm, 0.077 mg mL-1) and potassium
dichromate (DL50 84.05 ppm, 0.084 mg mL-1). On the other
hand, compounds 6-9 showed no activity detected at
concentration up to 200 ppm, indicating that modification
at C-13 or C-14 decreased the shrimp lethality. In light of
these results, we decided to examine further the cytotocity
profile of the synthesized macrolactones.
Uncontrolled proliferation is an universal property of
tumor cells, thus investigation of the cellular growth control
mechanism has contributed to the understanding of
carcinogenesis and the discovery of compounds with
specific antineoplastic activity.23 For this purpose, all of
the synthesized macrolides were submitted to human tumor
cell growth inhibition screening. The cytotoxic evaluation
against lymphoblastic leukemia (CEM), breast cell line
(MCF-7), human colon (HCT-8), and murine skin (B16),
was accomplished by the MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-tetrazolium bromide] microassay
described by Mosmann.24 In this method, the cell viability
is determined by using a tetrazolium salt, which is reduced
to a coloured product due to chemical interactions with
enzymes present only in living metabolically active cells.25
Tetrazolium salts have also been used to improve detection
of drug cytotoxicity in a soft agar colony formation assay26
and exhibit the advantage over many other stains of being
nonlethal, allowing cells to be recovered, if desired. As
shown in Table 1, the assays shown that the compounds 6
and 7 inhibited the proliferation of all four tested cell lines,
2 was active against mammalian cells, while 8 was active
against HCT8 and MCF-7 cell lines.
Table 1. Cytotoxicity of compounds 2 and 6-10 based on tumor cell
growth inhibition
Compound Cell line
CI50 (μg mL-1, confidence range)
CEM HCT-8 B16 MCF-7
12.45 7.70 10.53
2 8.59-18.03 6.31-9.57 >25 9.63-11.51
12.48 9.01 16.76 9.96
6 5.5-21.09 5.86-13.86 11.73-23.96 7.09-13.99
11.13 11.0 11.8 4.32
7 7.91-15-49 8.81-13.7 1.11-125.0 3.47-5.37
14.78 14.52
8 >25 9.78-22.33 >25 11.62-18.14
9 >25 >25 >25 >25
10 >25 >25 >25 >25
0.02 0.04 0.03 0.20
Doxorubicin 0.01-0.02 0.03-0.05 0.02-0.04 0.17-0.24
aPositive control.
Figure 5. Numerical order of the atoms in acyclic and cyclic intermediates used for the NMR assignments.
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Interestingly, the macrolactone 7 exhibited unique
differential ex vivo activity against MCF-7 cells (Figure 6).
These findings suggest that the double bond at the benzylic
position may play an important role in assisting its cytotoxic
profile, as in the truncated macrolides oximidines. Pure
compounds could be considered satisfactory to warrant
further studies as an antineoplastic drug when they present
an IC50 values lower than 1 μg mL-1 or 1 μmol L-1.27 Efforts to
expand the investigation around 7 are currently underway
and will be reported in due course.
In order to verify whether the active substances acted
through membrane disruption, all the new chemical
entities (2 and 6-10) were tested for the ability to induce
lysis in mouse erythrocytes.28 The results showed that none
of them cause membrane damage.
Experimental
Instrumentation, chemical and solvents
The oxidative cleavages were performed with a
Welsbach T-408 ozonizator and the catalytic
hydrogenations in a Parr apparatus. Flash Column
Chromatography and Dry-Column Flash Chromatography
were carried out using silica gel Merck 60 Å (70-230 mesh)
and eluting with a gradient of hexane:ethyl acetate.
Analytical thin layer chromatography was performed on
precoated Merck silica gel (60F254/0.2 mm) plates using UV
light, 5% ethanolic phosphomolybdic acid or iodine
vapours to visualize the spots. Melting points were obtained
on a Köffler apparatus and are uncorrected. IR-FT spectra
were recorded on a Bomem Hartmann & Braun (MB – 100)
spectrometer. 1H and 13C-NMR were recorded on Mercury
plus Varian (7.05 T) and Bruker (17.60 T) spectrometers,
using CDCl3/TMS. 1H and 13C chemical shifts are reported
in parts per million (ppm) relative to TMS. High pressure
liquid chromatography electrospray mass spectroscopy
(HPLC-ESIMS) experiments were performed using a Quattro
II Micromass/Waters spectrometer.
Isolation of anacardic acids (1)
The shells (500 g) of cashew nuts from Anacardium
occidentale (Ceará, Brazil) were extracted in a Soxhlet
extractor with commercial 95% ethanol (2.0 L) during 6 h,
yielding a crude extract (CNSL, 157 g, 31% by weight).
Anacardic acids (1) were removed in 61% from CNSL
(15.25 g) either by precipitation with lead nitrate or
calcium hydroxide.18 The spectral properties were identical
to those reported in the literature.29
Methyl anacardate methyl ethers (3)
A 500 mL three necked round-bottom flask fitted with
a mechanical stirrer was charged with anacardic acids (15
g, 43 mmol, average molecular wt 358), dichloromethane
(200 mL), 3 mol L-1 sodium hydroxide solution (60 mL)
and Aliquat® 336 (1.7 g, 10 mol%). To this mixture was
added dimethyl sulphate (20 mL; 215 mmol). After 2 h, at
room temperature, a cloudy emulsion initially formed
became a clear two-phase mixture to which was added 100
mL of a 2 mol L-1 ammonium hydroxide solution. After
stirring for 30 min at room temperature, the organic phase
was washed with water (3 x 50 mL), brine (2 x 50 mL), and
dried over sodium sulphate. Evaporation of the solvent
furnished a brown residue which was chromatographed on
silica gel (hexane-ethyl acetate, 9:1) to give 319 as a
colourless oil (14.3 g; 95%). IR (film) ν
max
/cm-1: 3008,
2927, 2855, 1735, 1585, 1470, 1432, 1268. 1H NMR (300
MHz, CDCl3) δ: 7.26 (t, J 8.40 Hz, 1H, ArH-4), 6.82 (d, J
7.8 Hz, ArH-5), 6.77 (d, J 8.7 Hz, ArH-3), 5.88-5.75 (m,
=CH), 5.46-5.28 (m, =CH), 5.08-4.95 (m, =CH), 3.90 (s,
COOCH3), 3,81 (s, OCH3), 2.90-2.70 (m, =CCH2C=), 2.76-
2.50 (deformed t, J 8.0 Hz, CH2-7), 2.06-1.98 (m, J 8.0 Hz,
CH2-7), 1.62-1.53 (m, CH2), 1.38-1.23 (br, aliphatic side-
chain CH2), 0.88 (deformed t, J 7.0 Hz, CH3). 13C NMR (75
MHz, CDCl3): 168.88 (COOCH3), 156.18 (C-2), 141.26
(C-6), 130.31 (C-4), 130.17-114.28 (olefinic region),
123.40 (C-1), 121.42 (C-5), 108.28 (C-3), 55.78 (ArOCH3),
55.05 (COOCH3), 33.41-22.60 (aliphatic side-chain), 14.06
(terminal CH3, n = 0).
Methyl-2-methoxy-6-(8-hydroxyoctyl) benzoate (4)
A solution of 3 (3.0 g, 8.00 mmol average molecular wt
376) in dichloromethane (75 mL) and methanol (75 mL) at -
70 oC was treated with ozone until the reaction was shown to
be complete by thin layer chromatography (hexane-ethyl
Figure 6. Growth inhibition of the compound 7 against tumor cell
lines.
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acetate, 9:1). The reaction mixture was purged with nitrogen,
an excess of sodium borohydride (2.0 g) was added, and the
resulting mixture was stirred at room temperature overnight.
After addition of water (10 mL), the reaction mixture was
hydrolysed with 10% hydrochloric acid (20 mL) and then
extracted with ethyl acetate (3 x 30 mL). The combined
extracts were washed with brine (3 x 30 mL), dried over sodium
sulphate and evaporated. The residue was chromatographed
on silica gel (hexane-ethyl acetate, 2:1) to afford the pure
alcohol 416 as a solid (1.88 g; 79%, mp 108-109 °C). IR (KBr)
ν
max
/cm-1: 3400, 2931, 1734, 1600, 1470, 1268, 1268, 1075.
1H NMR (300 MHz, CDCl3) δ: 7.24 (t, J 8.2 Hz, 1 H, ArH-4),
6.79 (d, J 8.2 Hz, 1 H, ArH-5), 6.73 (d, J 8.2 Hz, 1H, ArH-3),
3.88 (s, COOCH3), 3.79 (s, ArOCH3), 3.59 (t, J 6.5 Hz, 2 H,
CH2-14), 2.51 (dt, J 7.54 Hz, 2 H, CH2-7), 1.60 (m, 2 H, CH2-
8), 1.50 (m, 2 H, CH2-13), 1.40 (m, 2 H, CH2-12), 1.28 (m, 6 H,
CH2-9 to 11). 13C NMR (75 MHz, CDCl3) δ: 168.92 (COOCH3),
156.11 (C-2), 141.16 (C-6), 130.17 (C-4), 123.20 (C-1), 121.36
(C-5), 108.25 (C-3), 62.76 (C-14), 55.73 (ArOCH3), 52.06
(COOCH3), 33.32 (C-7), 32.59 (C-13), 30.97 (C-8), 29.24 (C-
9), 29.21 (C-10), 29.14 (C-11), 25.57 (C-12).
2-Methoxy-6-(8-hydroxyoctyl) benzoic acid (5)
To a solution of the hydroxyester 4 (1.37 g, 4.60 mmol)
in ethylene glycol (30 mL) was added a 10 mol L-1
potassium hydroxide solution (3.5 mL). After stirring at
165 °C for 1 h under an argon atmosphere, the reaction
mixture was acidified with 10% hydrochloric acid (15 mL)
and then extracted with ethyl acetate (3 x 30 mL). The
combined extracts were washed with brine (3 x 30 mL),
dried over sodium sulphate and evaporated. The pure acid
516 was obtained as a white solid by recrystalization from
hexane-ethyl acetate (1.04 g, 80%; mp 102-103 °C). IR
(KBr) ν
max
/cm-1: 3400, 2927, 1695, 1580, 1473, 1270. 1H
NMR (300 MHz, CDCl3) δ: 7.26 (dd, J 7.6 Hz, 1 H, ArH-4),
6.85 (d, J 8.4 Hz, 1 H, ArH-5), 6.83 (d, J 7.6 Hz, 1 H, ArH-3),
3.79 (s, 3 H, OCH3), 3.52 (t, J 6.3 Hz, 2 H, CH2-14), 2.90 (br,
1 H, OH), 2.60-2.50 (t, J 7.3 Hz, 2 H, CH2-7), 1.58 (m, 2 H,
CH2-8), 1.48 (m, 2 H, CH2-13), 1.40-1.38 (br, 8 H, CH2-9
to12). 13C NMR (75 MHz, CDCl3-CD3COCD3) δ: 168.51
(COOH), 155.41 (C-2), 140.37 (C-6), 129.27 (C-4), 123.20
(C-1), 120.87 (C-5), 107.72 (C-3), 61.44 (C-14), 54.96
(OCH3), 32.70 (C-7), 31.94 (C-13), 30.43 (C-8), 28.72 (C-
10), 28.58 (C-9), 28.45 (C-11), 25.00 (C-12).
4-Methoxy-7,8,9,10,11,12,14-octahydro-6-oxa-benzo-
cyclododecen-5-one (2)
To a refluxing solution of 2-chloro-1-methyl-
pyridinium iodide (0.84 g, 3.28 mmol) in dichloromethane
(50 mL) and acetonitrile (17 mL) was continuously and
uniformly added a solution of hydroxyacid 5 (0.20 g, 0.7
mmol) and triethylamine (0.78 mL, 5.6 mmol) in
dichloromethane (50 mL) over a period of 10 h, under a
nitrogen atmosphere. After addition, the reaction mixture
was refluxed for an additional 2 h. The solvent was removed
under reduced pressure and the residue was dissolved in
ethyl acetate (30 mL), washed with water (10 mL), diluted
phosphoric acid solution (10 mL), saturated sodium
bicarbonate solution (10 mL), brine (2 x 20 mL) and dried
over sodium sulphate. The organic phase was concentrated
to give a pale yellow residue, which was chromatographed
on silica gel (hexane-ethyl acetate, 9:1) to afford 2 as a
white solid [0.124 g, 66%, mp 58-60 °C]. IR (KBr) ν
max
/cm-1:
2929, 2857, 1727, 1598, 1584, 1470, 1437, 1264. 1H NMR
(500 MHz, CDCl3) δ: 6.84 (d, J 7.6 Hz, 1 H, ArH-1), 7.28 (t,
J 8.0 Hz, 1 H, ArH-2), 6.76 (d, J 8.3 Hz, 1 H, ArH-3), 4.45 (t,
J 5.3, 2 H, CH2-7), 3.83 (s, 3 H, OCH3), 2.59 (t, J 7.5 Hz, 2 H,
CH2-14), 1.89 (m, 2 H, CH2-8), 1.60 (m, 2 H, CH2-9), 1.71
(m, 2 H, CH2-13), 1.49 (m, 2 H, CH2-10), 1.41 (m, 2 H, CH2-
11), 1.43-1.36 (m, 2 H, CH2-12). 13C NMR (125 MHz,
CDCl3) δ: 169.19 (C-5), 156.40 (C-4), 141.76 (C-14a),
130.47 (C-2), 124.93 (C-1), 122.18 (C-3), 108.55 (C-4a),
67.10 (C-7), 56.26 (OCH3), 30.67 (C-14), 30.33 (C-8), 26.85
(C-10), 26.41 (C-11), 26.11 (C-12), 25.27 (C-9), 24.22 (C-




A mixture of the lactone 2 (0.74 g, 2.80 mmol), NBS
(0.60 g, 2.80 mmol) and benzoyl peroxide (catalytic amount)
in benzene (30 mL) was refluxed for 4 h, under an argon
atmosphere. The resultant brown mixture was filtered trough
a glass-fritted funnel. Water (10 mL) was added to the filtrate
and then extracted with ethyl acetate (3 x 20 mL). The
combined organic extracts was washed with saturated
sodium bicarbonate solution (20 mL), brine (2 x 20 mL),
and dried over sodium sulphate. The organic phase was
concentrated to furnish a yellow solid, which was
recrystallized from hexane-ethyl acetate to afford bromide
6 as white crystals (0.960 g, 100%, mp 116 °C). IR (KBr)
ν
max
/cm-1: 2932, 2856, 1730, 1599, 1593, 1472, 1437. 1H
NMR (500 MHz, CDCl3) δ: 7.29 (d, J 7.6 Hz, ArH-1), 7.40 (t,
J 8.1 Hz, 1 H, ArH-2), 6.84 (d, J 8.2 Hz, 1 H, ArH-3), 5.05 (m,
1 H, CH-14), 4,99 (m, 1 H, CH2-7), 3.96 (dt, J 11.15 and 1.84
Hz, 1 H, CH2-7’), 3.84 (s, 3 H, OCH3), 2.18 (br, 1 H, CH2-8),
1.73 (br, 1 H, CH2-8’), 1.73 (br, 2 H, CH2-12), 1.49-1.35 (m, 6
H, CH2-9 to 11). 13C NMR (125 MHz, CDCl3) δ: 167.56 (C-
5), 155.82 (C-4), 141.27 (C-14a), 131.29 (C-2), 122.64 (C-
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1), 121.29 (C-3), 110.56 (C-4a), 67.89 (C-7), 56.43 (OCH3),
49.3 (C-14), 39.55 (C-13), 26.69 (C-8), 26.07 (C-10), 26.53
(C-9), 25.07 (C-12), 23.77 (C-11). HR-ESIMS m/z [M+H]+
found 341.3620. Calc. for C16H22BrO3: 341.0752.
4-Methoxy-7,8,9,10,11,12-hexahydro-6-oxa-benzo-
cyclododec-13-en-5-one (7)
To a solution of bromide 6 (1.22 g, 3.56 mmol) in
benzene (30 mL), DBU (2.7 mL, 17.8 mmol) was added.
After stirring under reflux and an argon atmosphere for 10
h, the reaction mixture was quenched with 10% hydro-
chloric acid (15 mL) and then extracted with ethyl acetate
(3 x 20 mL). The combined organic extracts were washed
with 10% hydrochloric acid (20 mL), brine (2 x 20 mL),
and dried over sodium sulphate. The organic phase was
concentrated to furnish a yellow solid, which was
recrystallized from hexane-ethyl acetate to afford the trans-
unsaturated lactone 7 as white crystals (0.86 g, 94%, mp
79-80 °C). IR (KBr) ν
max
/cm-1: 2929, 2864, 1720, 1595,
1572, 1472, 1438, 1258, 1119, 1108, 1071. 1H NMR (500
MHz, CDCl3) δ: 7.40 (t, J 8.1 Hz, 1 H, ArH-2), 6.90 (d, J 7.7
Hz, 1H, ArH-1), 6.82 (d, J 8.3 Hz, 1H, ArH-3), 6.42 (d, J
15.8, 1H, CH-14), 5.88 (dt, J 15.8 and 7.3 Hz, 1 H, CH-13),
4.37 (t, J 5.5 Hz, 2 H, CH2-7), 3.85 (s, 3 H, OCH3), 2.18 (m,
2 H, CH2-12), 1.75 (m, 2 H, CH2-8), 1.57-1.40 (m, 6 H, CH2-
9 to 11). 13C NMR (125 MHz, CDCl3) δ: 168.44 (C-5),
156.73 (C-4), 138.85 (C-13), 138.55 (C-14a), 130.96 (C-
2), 129.26 (C-14), 122.44 (C-4a), 119.95 (C-1), 109.70 (C-
3), 66.04 (C-7), 56.32 (OCH3), 32.73 (C-12), 27.57 (C-10),
26.61 (C-8), 25.15 (C-11), 23.99 (C-9). HR-ESIMS m/z
[M+H]+ found 261.2289. Calc. for C16H21O3: 261.1490.
14-Methoxy-3,11-dioxa-tricyclo[11.4.0.02,4]heptadeca-
1(17),13,15-trien-12-one (8)
To a solution of unsaturated lactone 7 (0.10 g, 0.38
mmol) in dichloromethane (2 mL) was added drop wise a
solution of m-CPBA (0.13 g, 2.0 eq) in dichloromethane
(2 mL). The reaction mixture was stirred for 4 h, and then
diluted with ethyl acetate (20 mL). The organic phase was
washed with saturated sodium bicarbonate solution (10
mL), brine (2 x 10 mL), and dried over sodium sulphate.
The organic phase was concentrated to give a yellow solid,
which was recrystallized from hexane-ethyl acetate to
afford epoxide 8 as white crystals (0.09 g, 98%, mp 128-
129 °C). IR (KBr) ν
max
/cm-1: 2958, 2922, 2849, 1728, 1600,
1472, 1444, 1379, 1262. 1H NMR (500 MHz, CDCl3) δ:
7.35 (t, J 8.1 Hz, 1 H, ArH-2), 6.90 (d, J 8.3 Hz, 1 H, ArH-3),
6.83 (d, J 7.8, 1 H, ArH-1), 4.28 (dt, J 11.0 and 3.2 Hz, 1 H,
CH2-7), 4.55 (td, J 11.2 and 2.8 Hz, 1 H, CH2-7), 3.86 (s, 3
H, OCH3), 3.59 (d, J 1.3 Hz, 1 H, CH-14), 2.71 (dd, J 7.9
and 1.9, 1 H, CH-13), 2.18 (d, J 12.0 Hz, 1 H, CH2-12),
1.89-1.64 (m, 8 H, CH2-10 to 13), 1.56-1.36 (m, 1 H, CH2-
12). 13C NMR (125 MHz, CDCl3) δ: 167.57 (C-5), 156.77
(C-14a), 137.59 (C-4), 131.58 (C-2), 122.95 (C-4a), 116.04
(C-1), 110.87 (C-3), 68.53 (C-7), 64.32 (C-13), 57.91 (C-
14), 56.41 (OCH3), 29.53 (C-12), 28.27-24.80 (C-8 to C-




To a solution of epoxide 8 (0.10 g, 0.36 mmol) in
absolute ethanol (5 mL) was added 5% palladium on
carbon (0.03 g, 0.04 eq). The mixture was shaker in a Parr
apparatus, under hydrogen atmosphere (4 atm) until the
reaction was shown to be complete by TLC (hexane-ethyl
acetate, 2:1). After 2 h, the reaction mixture was filtered
over Celite®. The filtrate was concentrated under reduced
pressure and the yellow residue was flash chromatographed
on silica gel (hexane-ethyl acetate, 4:1) to give the pure
alcohol 9 as white crystals (0.98 g, 97%, mp 109-110 °C).
IR (KBr) ν
max
/cm-1: 3487, 3411, 2956, 2853, 1721, 1702,
1598, 1585, 1472, 1438, 1267, 1296. 1H NMR (500 MHz,
CDCl3) δ: 7.30 (d, J 8.1 Hz, 1 H, ArH-2), 6.95 (d, J 7.6 Hz,
1H, ArH-1), 6.83 (d, J 8.3 Hz, 1 H, ArH-3), 4.73 (m, 1 H,
CH2-7), 4.14 (td, J 11.2 and 2.1 Hz, 1 H, CH-7’), 3.96 (m,
1H, CH-13), 3.83 (s, 3 H, OCH3), 3.00 (dd, J 13.9 and 3.9
Hz, 1 H, CH2-14), 2,54 (dd, J 13.9 and 7.21 Hz, 1 H, CH2-
14’), 1.79 (m, 2H, CH2-12), 1.64-1.41 (m, 8 H, CH2-8 to11).
13C NMR (125 MHz, CDCl3) δ: 169.01 (C-5), 156.86 (C-
4), 137.67 (C-14a), 130.46 (C-2), 125.04 (C-1), 123.36 (C-
3), 109.50 (C-4a), 72.59 (C-13), 67.40 (C-7), 56.34 (OCH3),
38.98 (C-14), 35.54-22.25 (C-8 to C-12). HR-ESIMS m/z
[M+H]+ found 279.2295. Calc. for C16H23O4: 279.1596.
14-Methoxy-7,8,9,10,11,12-hexahydro-14H-6-oxa-
benzocyclododecene-5,13-dione (10)
To a solution of alcohol 6 (0.10 g, 0.36 mmol) in ether
(3 mL) was added Jones reagent (2.7 mL). After stirring for
1 h, the reaction mixture was quenched with ethanol (about
0.5 mL), diluted with brine (10 mL) and then extracted
with ethyl acetate (3 x 10 mL). The combined organic
extracts were washed with brine (3 x 10 mL), and dried
over sodium sulphate. The organic phase was concentrated
to give a yellow residue which was flash chromatographed
on silica gel (hexane-ethyl acetate, 4:1) affording the pure
keto lactone 10 as white crystals (97 mg, 96%, mp 91-92
°C). IR (KBr) ν
max
/cm-1: 2946, 2861, 1721, 1587, 1473,
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1438, 1332, 1297, 1267, 1194, 1123. 1H NMR (500 MHz,
CDCl3) δ: 7.33 (t, J 7.9 Hz, 1 H, ArH-2), 6.86 (d, J 8.4 Hz, 1
H, ArH-3), 6.80 (d, J 7.6 Hz, 1 H, ArH-1), 4.41 (t, J 5.0 Hz, 2
H, CH2-7), 3.83 (s, 2 H, CH2-14), 3.82 (s, 3 H, OCH3), 2.47
(t, J 6.2 Hz, 2 H, CH2-12), 1.79 (m, 2H, CH2-11), 1.76 (m,
2H, CH2-8), 1.50 (m, 2 H, CH2-9), 1.46 (m, 2 H, CH2-10).
13C NMR (125 MHz, CDCl3) δ: 208.22 (C-13), 168.42 (C-
5), 156.89 (C-4), 132.74 (C-14a), 130.70 (C-2), 124.72 (C-
3), 124.11 (C-1), 110.24 (C-4a), 66.54 (C-7), 56.3 (OCH3),
46.83 (C-14), 42.25 (C-12), 27.14 (C-8), 24.94 (C-10),
23.67 (C-9), 23.41 (C-11). HR-ESIMS m/z [M+H]+ found
277.2076. Calc. for C16H21O4: 277.1440.
Cytotoxicity assays
Brine shrimp lethality assay. Brine shrimp Artemia
salina encysted eggs (Maramar) were incubated in
simulated seawater at 28°C during 48 h with artificial light.
The samples were dissolved in 200 μL of DMSO plus 20
μL of artificial seawater. Serial dilutions (triplicate) were
prepared from the same solution. Metanauplii (10 units)
was added to each set of tubes containing the samples and
the cultures were incubated for additional 24 h. Controls
containing DMSO were included in each set of experiments.
Lapachol and potassium dichromate were used as reference
standards. LC50 (after 24 h) were calculated by Probit
analysis.
Tumor cell growth inhibition assays. Adherent cells
(0.2 x 105 cell 100 μL-1) and suspension cells (0.5 x 106
cells 100 μL-1) were seeded in 96 well microplates (Nucnck)
and pre-incubated for 24 h in order to allow cell attachment.
For the suspension cells this is not necessary. After plating
the cells, fresh medium (100 μL) containing various
concentrations (0.39 and 25 mg mL-1) of the samples was
added to the cultures, then the cells were incubated for 72
h. Cell survival was evaluated by adding MTT tetrazolium
salt solution with fresh medium. Doxorubicin (Doxolem®,
Zodiac Produtos Farmacêuticos S/A, Brazil) was used as
positive control. After 3 h incubation at 37 oC, 150 μL of
DMSO was added to dissolve the precipitate of reduced
MTT. Microplates were then shaken for 15 min, and the
absorbance was determined at 550 nm with a multiwell
scanning spectrophotometer. CEM (human acute
lymphoblastic leukemia), MCF-7 (breast cell line), HCT-8
(human colon) and B16 (murine skin) were maintained in
RPMI 1640 (Gibco BRL), containing 10% fetal bovine
serum (FBS; Gibco BRL), 1% penicillin and streptomycin
solution (Life Technologies), and incubated at 37 °C in
5% CO2 atmosphere.
Hemolytic assay. The test was performed in 96-well
plates. Each well received 100 μL of 0.85% saline
containing 10 mmol L-1 calcium chloride solution. The
first well was the negative control that contained only the
vehicle (DMSO 10%) and, in the second well, 50 μL of the
test sample and 50 μL of brine were added. The compounds
were tested at concentrations ranging from 0.39 to 200 μg
mL-1. The serial dilution continued until the 11th well. The
last well received 20 μL of 0.1% triton X-100 (in 0.85%
saline) to obtain 100% hemolysis (positive control). Then,
each well received 100 μL of a 2% suspension of mouse
erythrocytes in 0.85% saline containing 10 mmol L-1
calcium chloride solution. After incubation at room
temperature for 30 min and centrifugation, the supernatant
was removed and the liberated hemoglobin was measured
spectroscopically as absorbance at 540 nm.
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